The 7th Annual Perspectives in Thoracic Cancer

Last Modified: August 11, 2002

Conference Dates: October 4 - 5, 2002
Conference Location: New York, New York, USA

Sponsoring Group: Imedex, Inc.

Conference Web Page URL:

Topics Covered: Imaging and Surgical Staging in NSCLC, Management of Resectable Disease, Management of Metastatic/Recurrent Disease, Malignant Mesothelioma and Mediastinal Germ Cell Tumors, Esophageal Cancer, Small Cell Lung Cancer

Conference Objectives: After successfully completing this continuing medical education program participants should be able to:

  • Discuss the merits of the available methods for staging of non-small cell lung cancer
  • Recommend the most appropriate management approaches for resectable, non-resectable and metastatic non-small cell lung cancer
  • Recommend the most appropriate management strategy for esophageal cancer
  • Recommend appropriate management strategies for mesothelioma and mediastinal germ cell tumors

Who Should Attend: This educational program is intended for oncologists, radiation therapists, thoracic surgeons and other physicians in active clinical practice interested and/or involved in the management of patients with thoracic cancer. No specialized knowledge or skills other than a general familiarity with cancer and its treatment is required for successful participation in this program.

Conference Fees: $225 by August 12; $325 by September 27; $425 after September 27. $99 Nurses, Residents and Fellows

Continuing Education: Yes

Miscellany: Imedex7 USA, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Imedex7 USA, Inc. designates this continuing medical education activity for a maximum of 15.5 credit hours in Category 1 of the Physician's Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

ATS: Lung Cancer Diagnosis 7 Percent With Low-Dose CT

May 23, 2013

Preliminary rate of diagnosis 7 percent among patients at Boston Veterans Affairs Medical Center

ATS: Sleep Apnea Tied to Increased Risk of Cancer Death

May 22, 2012

Dose-response association seen with risk of cancer mortality increases with severity of apnea

2002 to 2008 Saw Increase in Partial Nephrectomy Use

Feb 20, 2012

For patients with renal masses, use of partial nephrectomy increased from 15.3 to 24.7 percent